THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Safety review boosts hopes for return of MS drug

No more cases of brain disease

By Jeffrey Krasner
Globe Staff / August 10, 2005

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biogen Idec Inc. said yesterday it screened patients who took the multiple sclerosis drug Tysabri and didn't find any new cases of the rare brain disease that led the company to pull it off the market. (Full article: 1057 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass